Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer
The study will be a prospective open-label single-center study in previously treated patients with Non Small Cell Lung Cancer (NSCLC). Treatment efficacy and safety of the combination of Oshadi D and Oshadi R with Docetaxel will be will be evaluated.

Patients will receive Docetaxel in combination with Oshadi D and Oshadi R. Patient will be evaluated throughout the study for safety and tolerance to multiple dose regimens of Oshadi D and Oshadi R.

CT or MRI imaging will be performed prior to treatment initiation and at the end of every 3 Docetaxel cycles (12 weeks). In case of disease progression, dose augmentation will be considered or subsequent therapy.
Carcinoma, Non-Small-Cell Lung
DRUG: Oshadi D and Oshadi R|DRUG: Docetaxel
overall survival time, overall survival of the patient, 12 months
Adverse events and serious adverse events occurence, Adverse events and serious adverse events occurred during the study, One month following treatment initiation|Patient report outcome, To assess patients quality of life by QLC30 questionnaire, 12 months
Progression Free Survival (PFS), time from treatment initiation to documentation of disease progression or death), 12 months|Duration of Response (DoR);, response duration to the drug, 12 months|Change in tumor size, changes in tumor size, 12 weeks
The study will be a prospective open-label single-center study in previously treated patients with Non Small Cell Lung Cancer (NSCLC). Treatment efficacy and safety of the combination of Oshadi D and Oshadi R with Docetaxel will be will be evaluated.

Patients will receive Docetaxel in combination with Oshadi D and Oshadi R. Patient will be evaluated throughout the study for safety and tolerance to multiple dose regimens of Oshadi D and Oshadi R.

CT or MRI imaging will be performed prior to treatment initiation and at the end of every 3 Docetaxel cycles (12 weeks). In case of disease progression, dose augmentation will be considered or subsequent therapy.